Related Experiment Video

Updated: Aug 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

HIV drug resistance surveillance: summary of an April 2003 WHO consultation

Stefano Lazzari1, Annapaola de Felici, Howard Sobel

  • 1World Health Organization, Geneva, Switzerland. lazzaris@who.int

AIDS (London, England)
|August 24, 2004
PubMed

Insights

Antiretroviral drug resistance threatens HIV treatment efficacy. The WHO Global HIV Drug Resistance Surveillance Programme monitors resistance trends and develops strategies to minimize its spread, facing implementation challenges.

Area of Science:

  • Infectious Diseases
  • Epidemiology
  • Public Health

Background:

  • Antimicrobial agent use, including antiretroviral therapy, can select for drug-resistant microorganisms.
  • HIV drug-resistant strains pose a significant threat to current treatment efficacy and global access to care.

Purpose of the Study:

  • To enhance and enable the response to antiretroviral drug resistance.
  • To assess geographical and temporal trends in HIV drug resistance.
  • To understand determinants and identify strategies to minimize HIV drug resistance emergence, evolution, and spread.

Main Methods:

  • Establishment of the WHO Global HIV Drug Resistance Surveillance Programme.
  • Development and field-testing of tools and guidelines for monitoring HIV resistance.
  • Utilizing a global network of experts and collaborating institutions.

Main Results:

  • Progress has been made in establishing a global surveillance network.
  • Tools and guidelines are being developed for regular monitoring, especially in treatment-naive patients.

Conclusions:

  • The WHO Global HIV Drug Resistance Surveillance Programme is crucial for combating HIV drug resistance.
  • Despite progress, significant challenges remain in the full implementation of this vital program.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...